#B. Braun #Tromethamine #EXCEL IV

B. Braun Introduces Tromethamine Injection in EXCEL® IV Container

B. Braun Medical Inc., a prominent name in smart infusion therapy and pain management, announced today the introduction of its latest product: the Tromethamine Injection packaged in a flexible EXCEL® IV Container. This product aims to fulfill the diverse needs of healthcare providers and their patients, improving administration efficiency and safety.

Product Highlights

The Tromethamine Injection is notably manufactured in EXCEL IV Containers, which are designed without the use of harmful substances like DEHP, PVC, or natural rubber latex. This reflects B. Braun's commitment to ensuring both patient and environmental safety. The product is produced at the company's Irvine, California facility and will be available in the U.S. market.

Key Advantages of the EXCEL IV Container

As highlighted by Jeremy Greene, Senior Director of Pharma Marketing at B. Braun, the traditional glass bottles used for Tromethamine can pose significant risks. These glass containers are prone to shattering, potentially causing safety hazards in pharmacies and bedside settings. In contrast, the EXCEL IV Container provides a flexible and shatter-resistant alternative, making it safer and easier for healthcare providers to store, handle, and administer the medication.

Composition and Dosage Information

Each 100 mL of this new Tromethamine Injection formulation contains 3.6 grams of Tromethamine (30 mEq) dissolved in water for injection. The solution is classified as hypertonic, with a calculated osmolarity of 385 mOsmol/L, and a pH range of 8.4 to 8.7, ensuring it meets the necessary pharmacological standards for patient safety and efficacy.

Important Safety Information

While the product is a significant advancement, healthcare professionals should be aware of certain contraindications associated with the Tromethamine Injection. The injection should not be used in patients with uremia and anuria or those suffering from chronic respiratory acidosis or salicylate intoxication, particularly in neonates. Providers are encouraged to review the full prescribing information for comprehensive safety details.

About B. Braun

B. Braun Medical Inc. stands out as a leader in the realm of smart infusion therapy and effective pharmacy solutions. With a mission to enhance patient satisfaction and outcomes, B. Braun is dedicated to providing healthcare professionals with products and services that streamline their work and allow them to concentrate on their most significant responsibility: their patients.

The company operates from its headquarters in Bethlehem, Pennsylvania, and is part of the larger B. Braun Group, which comprises various subsidiaries throughout the U.S., including B. Braun Interventional Systems and Aesculap®. Employing over 8,500 staff across more than 30 locations in North America, B. Braun remains committed to innovation in healthcare. Globally, the company boasts a workforce of over 64,000 across 64 countries, working under the guiding principle of